Moderna (MRNA) Cash & Equivalents (2017 - 2026)
Moderna (MRNA) reported Cash & Equivalents of $1.72 billion for Q2 2026, up 34.7% from $1.28 billion a year earlier but down 9.7% from the prior quarter.
Powered by 
Analysis
Moderna (MRNA) Cash & Equivalents (2017 - 2026) Analysis & Trends
At the end of FY2025, Moderna posted Cash & Equivalents of $2.6 billion, up 34.7% from FY2024.
- Cash & Equivalents has a five-year compound annual growth rate of -0.2% (FY2020 to FY2025).
- By year, Cash & Equivalents came in at $1.93 billion in FY2024 (-33.7%), $2.91 billion in FY2023 (-9.3%), $3.21 billion in FY2022 (-53.2%) and $6.85 billion in FY2021 (+161.0%).
- Five-year quarterly Cash & Equivalents spans a low of $1.13 billion in Q3 2025 and a high of $6.85 billion in Q4 2021.
- Year over year, Cash & Equivalents has now increased in each of the last three quarters, with an average decline of 11.4% over the last eight quarters.
- The high point for year-over-year Cash & Equivalents in five years was Q3 2021 (growth of 268.5%); the low point was Q4 2022 (a decline of 53.2%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $1.91 billion (Q1 2026), $2.6 billion (Q4 2025) and $1.13 billion (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,122.91 Bn | 1,091.50 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 615.09 Bn | 533.62 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 504.75 Bn | 477.86 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 360.18 Bn | 314.55 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 292.05 Bn | 256.04 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 256.09 Bn | 229.78 Bn | 12.86 Bn | 4.90 Bn |
| 7 | Amgen | 233.63 Bn | 189.02 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 194.49 Bn | 168.69 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 168.35 Bn | 114.99 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Moderna | 85.93 Bn | 65.29 Bn | 52.00 Mn | 1.72 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.72 Bn |
| Mar 31, 2026 | 1.91 Bn |
| Dec 31, 2025 | 2.60 Bn |
| Sep 30, 2025 | 1.13 Bn |
| Jun 30, 2025 | 1.28 Bn |
| Mar 31, 2025 | 1.62 Bn |
| Dec 31, 2024 | 1.93 Bn |
| Sep 30, 2024 | 1.64 Bn |
| Jun 30, 2024 | 2.48 Bn |
| Mar 31, 2024 | 2.05 Bn |
| Dec 31, 2023 | 2.91 Bn |
| Sep 30, 2023 | 2.93 Bn |
| Jun 30, 2023 | 3.80 Bn |
| Mar 31, 2023 | 3.44 Bn |
| Dec 31, 2022 | 3.21 Bn |
| Sep 30, 2022 | 3.03 Bn |
| Jun 30, 2022 | 2.87 Bn |
| Mar 31, 2022 | 5.05 Bn |
| Dec 31, 2021 | 6.85 Bn |
| Sep 30, 2021 | 5.55 Bn |
API Access
Moderna Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=MRNA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "MRNA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=MRNA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();